NCT06382103Recruiting
Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy
Source: ClinicalTrials.gov · Last updated 26 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Blood samples will be tested to identify circulating tumor DNA and plasma protein levels to potentially improve prediction of long term prognosis and guide treatment options of patients with hepatocellular carcinoma underwent surgical resection.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 240 (estimated)
- First submitted
- 15 Apr 2024
- Start date
- 15 May 2024
- Primary completion date
- 20 May 2025
- Lead sponsor
- Shanghai Zhongshan Hospital
- NCT number
- NCT06382103
What you commit to
- Study type: Observational
- Planned participants: 240
- From 15 May 2024 to the primary completion date, 20 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any other concurrent malignancy.
Other illness
- Patients with secondary liver cancer, or intrahepatic cholangiocarcinoma.
- History of organ transplant or hepatic encephalopathy.
Who the study is looking for
- Patients with a first diagnosis of HCC.
- Patients with HCC who are to undergo surgical treatment, with or without neoadjuvant therapy.
- Ability to obtain tissue sample for ctDNA analysis and detectable baseline ctDNA level.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhongshan Hospital,Fudan University Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.